GlassScriptPhysician profile
Thomas S Pearce
NPI 1053306589
$14,505.65
in general payments reported to CMS, 2019-2025
55 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,379 · 2020: $1,137 · 2021: $2,452 · 2022: $2,510 · 2023: $2,909 · 2024: $2,011 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,961 · Education: $66.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,960.89 |
| Education | $66.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,127.32 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,397.53 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Pfizer INC. | $1,136.58 | 2019-2025 | |
| Novo Nordisk INC | $790.38 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $781.18 | 2019-2023 | Jardiance, Spiriva Respimat |
| Janssen Pharmaceuticals, INC | $687.62 | 2019-2024 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $553.33 | 2020-2025 | Austedo Xr, Austedo, Austedo Xr |
| Amgen INC. | $522.40 | 2019-2025 | Repatha, Evenity, Prolia |
| Glaxosmithkline, LLC. | $465.71 | 2019-2023 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $442.70 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $419.44 | 2019-2025 | Trintellix |
| Arbor Pharmaceuticals, INC. | $391.17 | 2019-2022 | |
| Allergan, INC. | $385.36 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $375.99 | 2022-2025 | |
| Azurity Pharmaceuticals, INC. | $325.56 | 2023-2024 | Edarbi, Edarbi |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Pearce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.